Clinical Trials

Title   A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan (OPC 41061, 30 mg to 120 mg/day, Split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease (156-13-211)
Description   The purpose of the study is to evaluate and describe the long term safety of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD
IRB Number   14-257
Status   Active
Start Date   11/11/2014
Principal Name   Michael Culpepper, MD
Contact Name   Erica Sutherland

Email Newsletters

Connect With Us